I'm incredibly proud to share our paper on the preclinical evaluation of the BNT164 mRNA tuberculosis vaccine candidates.
Now online in the final version at Nature Immunology.
www.nature.com/articles/s41...
Here the authors characterize mRNA-based tuberculosis vaccine candidates BNT164a1 and BNT164b1 and show that they are immunogenic, well tolerated and efficacious in preclinical animal models.